Most-Downgraded Stocks NASDAQ:EDIT Editas Medicine - EDIT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $9.07 -0.02 (-0.22%) (As of 01/26/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.74▼$9.3050-Day Range$7.81▼$10.9552-Week Range$7.70▼$21.59Volume1.73 million shsAverage Volume2.00 million shsMarket Capitalization$623.68 millionP/E RatioN/ADividend YieldN/APrice Target$16.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Editas Medicine MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside85.9% Upside$16.86 Price TargetShort InterestBearish32.20% of Shares Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment0.60Based on 16 Articles This WeekInsider TradingSelling Shares$17,481 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.15) to ($2.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.32 out of 5 starsMedical Sector291st out of 1,048 stocksBiological Products, Except Diagnostic Industry45th out of 168 stocks 4.1 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 4 buy ratings, 8 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.86, Editas Medicine has a forecasted upside of 85.9% from its current price of $9.07.Amount of Analyst CoverageEditas Medicine has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted32.20% of the outstanding shares of Editas Medicine have been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in Editas Medicine has recently increased by 2.26%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEditas Medicine has received a 74.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Editas Medicine is -0.84. Previous Next 2.6 News and Social Media Coverage News SentimentEditas Medicine has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Editas Medicine this week, compared to 2 articles on an average week.Search Interest20 people have searched for EDIT on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 21 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -5% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,481.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions69.67% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to grow in the coming year, from ($3.15) to ($2.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Editas Medicine (NASDAQ:EDIT) StockEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Read More Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address EDIT Stock News HeadlinesJanuary 25, 2023 | marketbeat.comHow Will Early 2023 Layoffs Affect These 5 Biotech Stocks? (EDIT)Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.January 26, 2023 | benzinga.comMorgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $7January 27, 2023 | UNKNOWN (Ad)Hot craft spirits opportunity you don't want to missAward winning products. Global distribution. New distillery. New products.January 26, 2023 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Price Target Cut to $7.00January 26, 2023 | americanbankingnews.comEditas Medicine, Inc. to Post FY2024 Earnings of ($2.34) Per Share, SVB Leerink Forecasts (NASDAQ:EDIT)January 26, 2023 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Stock Price Up 4% Following Analyst UpgradeJanuary 25, 2023 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) PT Raised to $7.00 at SVB LeerinkJanuary 24, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Intercept Pharma (ICPT), Synlogic (SYBX) and Editas Medicine (EDIT)January 27, 2023 | UNKNOWN (Ad)Hot craft spirits opportunity you don't want to missAward winning products. Global distribution. New distillery. New products.January 20, 2023 | finance.yahoo.comEditas (EDIT) Moves Ahead With its Portfolio ReprioritizationJanuary 19, 2023 | marketwatch.comCRISPR Cas9 Market Detailed Analysis of Current Scenario with Growth Forecasts to 2028January 19, 2023 | msn.comEditas to sell natural killer cell programs to ShorelineJanuary 11, 2023 | finance.yahoo.comBiotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & MoreJanuary 10, 2023 | markets.businessinsider.comAnalyst Expectations for Editas Medicine's FutureJanuary 10, 2023 | finance.yahoo.comEditas (EDIT) Dips on Portfolio Reprioritization, To Cut JobsJanuary 9, 2023 | finanznachrichten.deEditas Medicine, Inc.: Editas Medicine Announces Strategic Updates and Portfolio ReprioritizationJanuary 9, 2023 | msn.comEditas cuts 20% staff in portfolio overhaulJanuary 9, 2023 | markets.businessinsider.comEditas Medicine To Reduce Headcount By 20% As Part Of Reprioritization, CSO To StepdownJanuary 9, 2023 | marketwatch.comEditas Medicine tumbles more than 7% after announcing job cuts, restructuringJanuary 5, 2023 | marketwatch.comLeber Congenital Amaurosis (LCA) Market Opportunities, Size, Share, Emerging Trends, And Forecast To 2028January 4, 2023 | marketwatch.comCRISPR and CRISPR-Associated (Cas) Genes Market : Projections and Regional Outlook, Set for Rapid Growth and Trend by 2023 To 2028January 4, 2023 | finance.yahoo.comEditas Medicine to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 6, 2022 | finance.yahoo.comEditas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell DiseaseDecember 1, 2022 | finance.yahoo.comEditas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell DiseaseNovember 28, 2022 | finance.yahoo.comEditas (EDIT) Declines More Than 30% in 3 Months: Here's WhyNovember 23, 2022 | finance.yahoo.comHere's Why Editas (EDIT) Looks Ripe for Bottom FishingNovember 18, 2022 | finance.yahoo.comWhy Editas Medicine's Shares Are Falling ThursdaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address EDIT Company Calendar Last Earnings11/02/2022Today1/26/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDIT CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees264Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.86 High Stock Price Forecast$36.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+85.9%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($2.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,500,000.00 Net Margins-784.32% Pretax Margin-784.32% Return on Equity-41.33% Return on Assets-33.35% Debt Debt-to-Equity RatioN/A Current Ratio10.09 Quick Ratio10.09 Sales & Book Value Annual Sales$25.54 million Price / Sales24.42 Cash FlowN/A Price / Cash FlowN/A Book Value$8.09 per share Price / Book1.12Miscellaneous Outstanding Shares68,763,000Free Float67,869,000Market Cap$623.68 million OptionableOptionable Beta1.90 Key ExecutivesMr. James C. Mullen (Age 64)Exec. Chairman Comp: $1.01MMs. Michelle Robertson (Age 56)CFO, Principal Accounting Officer, Treasurer & Assistant Sec. Comp: $641.74kDr. Mark S. Shearman (Age 63)Exec. VP & Chief Scientific Officer Comp: $639.89kDr. Bruce E. Eaton Ph.D. (Age 69)Exec. VP & Chief Bus. Officer Comp: $1.09MDr. Gilmore O'Neill (Age 59)Pres & CEO Dr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberDr. George McDonald Church Ph.D. (Age 69)Co-Founder & Scientific Advisory Board Member Dr. J. Keith Joung M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberDr. David R. Liu Ph.D.Co-Founder & Scientific Advisory Board MemberMr. Harry R. Gill III (Age 62)Sr. VP of Operations More ExecutivesKey CompetitorsImmaticsNASDAQ:IMTXPoseida TherapeuticsNASDAQ:PSTXScholar RockNASDAQ:SRRK4D Molecular TherapeuticsNASDAQ:FDMTSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsElmwood Wealth Management Inc.Sold 10,127 shares on 1/26/2023Ownership: 0.020%Sigma Planning CorpSold 3,911 shares on 1/24/2023Ownership: 0.018%Exchange Traded Concepts LLCBought 87,616 shares on 1/18/2023Ownership: 0.127%Green Alpha Advisors LLCBought 2,857 shares on 1/12/2023Ownership: 0.087%Michelle RobertsonSold 1,752 sharesTotal: $14,296.32 ($8.16/share)View All Insider TransactionsView All Institutional Transactions EDIT Stock - Frequently Asked Questions Should I buy or sell Editas Medicine stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 2 sell ratings, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares. View EDIT analyst ratings or view top-rated stocks. What is Editas Medicine's stock price forecast for 2023? 14 brokerages have issued 12-month price objectives for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $36.00. On average, they expect the company's stock price to reach $16.86 in the next twelve months. This suggests a possible upside of 85.9% from the stock's current price. View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts. How have EDIT shares performed in 2023? Editas Medicine's stock was trading at $8.87 at the beginning of 2023. Since then, EDIT shares have increased by 2.3% and is now trading at $9.07. View the best growth stocks for 2023 here. When is Editas Medicine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our EDIT earnings forecast. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings results on Wednesday, November, 2nd. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.06. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $5.86 million. Editas Medicine had a negative net margin of 784.32% and a negative trailing twelve-month return on equity of 41.33%. What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS). When did Editas Medicine IPO? (EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. What is Editas Medicine's stock symbol? Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT." Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by a number of institutional and retail investors. Top institutional investors include Exchange Traded Concepts LLC (0.13%), Green Alpha Advisors LLC (0.09%), McGuire Investment Group LLC (0.02%), Elmwood Wealth Management Inc. (0.02%) and Sigma Planning Corp (0.02%). Insiders that own company stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Editas Medicine's stock price today? One share of EDIT stock can currently be purchased for approximately $9.07. How much money does Editas Medicine make? Editas Medicine (NASDAQ:EDIT) has a market capitalization of $623.68 million and generates $25.54 million in revenue each year. The company earns $-192,500,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. How many employees does Editas Medicine have? The company employs 264 workers across the globe. How can I contact Editas Medicine? Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com. This page (NASDAQ:EDIT) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.